# R1 Clinical-Safety Review — oligodendroglioma (wave7)

VERDICT: APPROVE

goldens changed: no (intended: n/a — narrative content, no engine/rule change)

## 1. SAFETY — pass
No unsafe, misleading, or absolute directives. Every actionable claim is hedged
("can allow", "may be considered", "reasonable", "should be weighed"). Correctly
states there is no grade 4 oligodendroglioma (WHO 2021), that combined
chemoradiotherapy is the backbone, and that the disease remains eventually
progressive/incurable. The chemo-first-to-preserve-plasticity and staged-resection
statement (line 9) is appropriately qualified and does not push a directive. No
statement would cause harm if followed.

## 2. GROUNDING — pass
Treatment claims are consistent with DeVita 12th ed / NCCN standard of care:
molecular definition (IDH-mutant + whole-arm 1p/19q codeletion), codeleted survival
benefit of chemoRT vs RT alone (RTOG 9402-type "roughly twice as long"), CODEL
interim chemo-alone-worse signal, no level-1 support for chemo-alone, adjuvant PFS
doubling, EORTC early-vs-deferred RT (PFS benefit, no OS difference, better 1-yr
seizure control), no benefit from dose escalation, CDKN2A/B homozygous loss as an
adverse feature. No fabricated regimen. The two "new nodular enhancement = higher-
grade transformation" statements (lines 32, 37) are correctly relabelled
"(general oncology standard, not from DeVita's section on this disease)" — no
DeVita mis-attribution.

## 3. DOSE-FREE — pass
Independent grep for mg / m2 / AUC / Gy / cycle & fraction counts: zero hits. Only
non-dose numerals present (grades 2/3, 1p/19q, IDH1/2, "one year", response-rate
paraphrase, "12th ed"). Line 42 explicitly documents omitted RT dose/fractionation.

## 4. SCOPE — pass
Framed as decision-support: MDT framework, supportive/palliative input, urgent-
referral triggers. No directive overreach.

## 5. ADVERSARIAL FLAGS — clear
oligodendroglioma.verdict.md (round 2) verdict = CLEAN; all prior dose-leak and
mis-attribution flags resolved (nodular-enhancement claims relabelled). No residual
flagged claim remains in the sidecar. Nothing forces REVISE.

## Advisory (non-blocking)
- IDH-directed therapy (line 28) is framed as "investigational rather than
  standard." Since DeVita 12th ed, vorasidenib (INDIGO) reached approval for grade 2
  IDH-mutant glioma. The conservative "investigational" framing under-claims but does
  NOT mislead or harm (clinician still routed to standard chemoRT). Optional future
  refresh to note an approved IDH inhibitor exists for grade 2 disease; not required
  for approval.
